Hemostemix

HEM.V

Biotechnology · Healthcare

Price

C$0.07

+0.01 (+7.69%)

Market Cap

C$13.8M

Exchange

Toronto Stock Exchange Ventures

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+184.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 57.5M (2021) → 163.4M (2025)

Hemostemix Inc. is a small Canadian biotechnology company focused on developing cell-based therapies to treat diseases caused by poor blood flow. Its lead product, ACP-01, uses a patient's own blood stem cells to try to restore circulation in people with conditions like critical limb ischemia, a serious condition where blocked arteries can lead to amputation. The company targets patients who have run out of other treatment options, such as surgery or stents.

Hemostemix does not yet generate meaningful revenue, as ACP-01 is still in clinical development. It is listed on the TSX Venture Exchange and operates primarily in Canada, with a very small market capitalization typical of early-stage biotech firms. The company's approach of using a patient's own cells is designed to reduce rejection risks, which could be a differentiating factor, but the main risk is that clinical trials may fail to prove the therapy works well enough to win regulatory approval and reach commercial scale.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+64.4% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$2M/ year

↑ Rising (+83569% vs prior year)

R&D investment increasing — building for the future

Insider Activity

21.8%ownership

Insiders own a meaningful stake in the company

Cash Runway

~1 months

$319,236 cash & investments

Quarterly Free Cash Flow

Short runway — potential dilution ahead through share issuance

Cash watch

Hemostemix has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial